Clofarabine in relapsed lymphoma: What is the optimal dose?

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1230-1231

  Nabhan, Chadi ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; LARGE CELL LYMPHOMA; LETTER; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM TOLERATED DOSE; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOMA, NON-HODGKIN; MEDICAL ONCOLOGY; RECURRENCE; REMISSION INDUCTION; RESEARCH DESIGN;

EID: 68449091902     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903003251     Document Type: Letter

References (2)

1. Blum KA, Hamadani M, Phillips GS, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:349-356.
2. Nabhan C, Fried W, Galvez A, Venugopal P, Gozun P, Bitran J. Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL). J Clin Oncol 2008;26:ABstract 8564 (pp. 470).